How to Reconstitute PT-141 (Bremelanotide): Syringe Selection and Needle Gauge

What Is PT-141 (Bremelanotide) and Why Does Reconstitution Matter?

PT-141, generically known as bremelanotide, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It acts on melanocortin receptors MC3R and MC4R in the central nervous system to modulate sexual arousal pathways in both women and men. The FDA approved bremelanotide as Vyleesi (1.75 mg/0.3 mL auto-injector) in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women [1].

Compounded versions are dispensed as lyophilized (freeze-dried) powder in multi-dose vials, typically 10 mg. Lyophilization preserves peptide integrity during storage, but the powder must be reconstituted precisely before use. Errors in diluent volume, syringe calibration, or injection technique can produce significant dosing variance, which matters clinically because bremelanotide's side-effect profile, particularly transient blood pressure elevation, is dose-dependent [2].

Why Syringe Choice Directly Affects Dose Accuracy

A 0.1 mL error in a peptide drawn into a 3 mL syringe represents roughly 3% of total volume. In a 1 mL insulin syringe calibrated to 0.01 mL, that same 0.1 mL error becomes immediately visible. At the 1.75 mg target dose from a 5 mg/mL solution, you are drawing exactly 0.35 mL. Getting that right to the nearest 0.01 mL is far simpler with an insulin syringe than with any larger barrel.

Regulatory Context for Compounded PT-141

Compounded bremelanotide vials are prepared under USP General Chapter 797 standards for sterile compounding. These standards govern beyond-use dating, sterility testing, and container closure integrity [3]. Patients receiving compounded PT-141 should confirm their pharmacy holds a valid state sterile compounding license and follows Current Good Compounding Practice (CGCP) guidance per FDA's 503A and 503B frameworks [4].

Bacteriostatic Water: The Required Diluent

Why Bacteriostatic Water, Not Sterile Water

Bacteriostatic water for injection (BWFI) contains 0.9% benzyl alcohol as a preservative. That preservative matters for two reasons. First, it allows the reconstituted vial to be used across multiple draws over 28 to 30 days without sterility compromise. Sterile water for injection (SWFI) carries no preservative, so a multi-dose vial reconstituted with SWFI should technically be discarded after a single use or within 24 hours under USP 797 guidance [3].

Second, benzyl alcohol has a mild bacteriostatic effect that provides a meaningful safety margin during the 30-day use window. A 2018 stability analysis of preserved peptide formulations confirmed that benzyl alcohol-containing solutions maintained greater than 97% peptide purity at 4°C across 30 days compared to preservative-free controls [5].

Volume Calculation: 2 mL Per 10 mg Vial

Adding 2 mL of BWFI to a 10 mg vial produces a 5 mg/mL concentration. That is the standard starting point used in FDA clinical trials for bremelanotide, including the Phase III RECONNECT trial (N=1,267), where the 1.75 mg dose was delivered in 0.3 to 0.35 mL volume [2].

Some compounding pharmacies supply vials at different fill amounts (5 mg or 20 mg). The math scales linearly:

| Vial size | BWFI volume | Final concentration | |-----------|-------------|---------------------| | 5 mg | 1 mL | 5 mg/mL | | 10 mg | 2 mL | 5 mg/mL | | 20 mg | 4 mL | 5 mg/mL |

Always confirm the vial label's stated fill weight before calculating. Discrepancies greater than 5% from label claim should prompt a call to the dispensing pharmacy.

How to Add Bacteriostatic Water Without Damaging the Peptide

Aim the BWFI stream at the glass wall of the vial, not directly onto the lyophilized cake. Direct jetting disrupts the powder cake and can cause foaming, which introduces air bubbles that complicate accurate draw volume. Use a slow, steady plunger push. After injection of the diluent, gently swirl (do not shake) the vial until the powder fully dissolves. PT-141 typically dissolves within 30 to 60 seconds at room temperature [5].

Syringe Selection: The Right Tool for Every Step

Two-Syringe Protocol: Draw Needle vs. Injection Needle

Peptide reconstitution and injection are best handled as a two-step process using two different needles on the same syringe barrel, or two separate syringes:

1. Draw syringe or draw needle: A 21 to 23 gauge, 1-inch needle to puncture the septum and aspirate the solution cleanly. Larger gauge draws reduce coring of the rubber septum, minimizing particulate contamination. Coring risk increases sharply with needles coarser than 20 gauge, so 21 gauge is the practical minimum for septum puncture [6].

2. Injection syringe: A 1 mL insulin syringe with a 27 to 29 gauge, 0.5-inch fixed needle for the subcutaneous injection itself. The shorter, finer needle causes significantly less discomfort and is sized appropriately for the subcutaneous fat layer, which in most adults ranges from 8 to 20 mm in depth at the abdomen [7].

If you are using an insulin syringe with a fixed (non-removable) needle, you will draw through the fine injection needle rather than a separate draw needle. This is acceptable for multi-dose vials with soft, low-resistance rubber septa. Swap to a fresh syringe for each dose to maintain sterility.

Insulin Syringe Calibration and Reading the Scale

Standard U-100 insulin syringes hold 1 mL and are marked in 2-unit increments, where 1 unit equals 0.01 mL. The dose table below converts common PT-141 doses to insulin syringe units:

| PT-141 dose | Volume at 5 mg/mL | Insulin syringe units (U-100) | |-------------|-------------------|-------------------------------| | 1.0 mg | 0.20 mL | 20 units | | 1.25 mg | 0.25 mL | 25 units | | 1.75 mg (FDA std.) | 0.35 mL | 35 units | | 2.0 mg | 0.40 mL | 40 units | | 2.5 mg | 0.50 mL | 50 units |

Half-unit (0.005 mL) precision is achievable with standard insulin syringes. For doses below 1.0 mg, a 0.5 mL syringe (U-50) with 1-unit = 0.01 mL markings improves readability.

Why 27 to 29 Gauge for Subcutaneous Injection

Gauge describes needle inner diameter inversely: higher gauge equals finer needle. The subcutaneous injection of a peptide solution that is essentially water-viscosity requires no driving force, so 27 to 29 gauge needles are entirely adequate for flow while minimizing tissue trauma and pain.

A randomized crossover study comparing 25, 27, and 29 gauge needles for subcutaneous injections found statistically significantly lower pain scores (VAS scale) with 27 to 28 gauge versus 25 gauge (P<0.001) with no difference in dose delivery accuracy between gauges [8]. Needle length of 0.5 inches (12.7 mm) is appropriate for most adults; individuals with BMI <22 or very lean abdominal tissue may prefer the 45-degree insertion angle rather than the standard 90-degree angle to avoid intramuscular injection.

Step-by-Step Reconstitution Protocol

What You Need Before Starting

Gather all supplies before opening anything sterile:

• 10 mg PT-141 lyophilized vial from a licensed compounding pharmacy
• 2 mL bacteriostatic water for injection (BWFI) in a separate vial or pre-filled syringe
• One 1 mL insulin syringe with 28 or 29 gauge fixed needle
• One 21 to 23 gauge, 1-inch draw needle (if using a syringe with a removable needle hub)
• Alcohol prep pads (70% isopropyl alcohol)
• Sharps container
• Clean, flat, well-lit surface

Reconstitution Steps

Step 1. Wash hands with soap and water for at least 20 seconds. Dry with a clean paper towel.

Step 2. Wipe both vial tops (PT-141 and BWFI) with fresh alcohol pads. Allow 15 to 30 seconds to air dry. Wet alcohol degrades rubber septa over time.

Step 3. Draw 2 mL of BWFI using the draw needle (or the insulin syringe if using a fixed-needle syringe). Insert the needle at a slight angle to minimize coring.

Step 4. Invert the PT-141 vial. Insert the needle through the septum and slowly push the BWFI into the vial, directing the stream toward the glass wall.

Step 5. Remove the needle and gently swirl the vial for 30 to 60 seconds. Do not shake. Hold the vial to the light and confirm the solution is clear and colorless. Discard if you see cloudiness or visible particles.

Step 6. Label the vial with the reconstitution date and your name. Refrigerate at 2 to 8°C immediately.

Drawing a Dose

Step 7. When ready to inject, remove the vial from the refrigerator. Allow it to reach room temperature for 5 to 10 minutes to reduce injection discomfort.

Step 8. Wipe the vial septum with a fresh alcohol pad.

Step 9. Insert the insulin syringe needle into the vial, invert the vial, and slowly draw to the correct unit mark (35 units for the 1.75 mg dose).

Step 10. Withdraw the needle. Check for air bubbles. Tap the barrel gently and push air out before injecting.

Injection Technique for PT-141

Site Selection and Preparation

Subcutaneous injection sites suitable for PT-141 include the lower abdomen (at least 2 inches from the navel), the outer thigh, or the upper buttock. Rotate sites with each dose. Fixed repeat injections at the same location cause subcutaneous fat changes (lipohypertrophy) that alter absorption rates [9].

Clean the selected site with an alcohol pad and allow it to dry for 15 seconds.

Needle Angle and Insertion

Pinch a fold of skin between the thumb and forefinger to lift subcutaneous tissue away from muscle. Insert the needle at 90 degrees for individuals with adequate fat tissue (typically BMI >22). Use a 45-degree angle for lean individuals (BMI <22) to avoid accidental intramuscular injection, which could increase absorption speed and the likelihood of the transient blood-pressure elevation documented in RECONNECT trial participants [2].

Inject slowly over 5 to 10 seconds. Withdraw the needle at the same angle as insertion. Apply light pressure with a clean cotton ball. Do not rub.

Timing Relative to Sexual Activity

The FDA-approved Vyleesi label specifies administration at least 45 minutes before anticipated sexual activity [1]. Peak plasma concentration for bremelanotide occurs approximately 60 minutes post-injection [2]. Clinical use windows of 45 to 90 minutes before activity align with that pharmacokinetic profile.

Dosing Calculator: Working Out Your Exact Draw Volume

The following framework lets you calculate your draw volume for any vial concentration and dose:

Formula:

Draw volume (mL) = Target dose (mg) / Concentration (mg/mL)

Insulin syringe units:

Units = Draw volume (mL) x 100

Example (1.75 mg dose from a 5 mg/mL vial):

Draw volume = 1.75 / 5 = 0.35 mL Units = 0.35 x 100 = 35 units on a U-100 syringe

If your pharmacy supplies a 10 mg/mL concentration (achieved by adding only 1 mL BWFI to a 10 mg vial), the same 1.75 mg dose requires only 0.175 mL, or 17.5 units. That is close to a half-unit reading and introduces more measurement error. The 5 mg/mL standard concentration is preferred specifically because the draw volumes align cleanly with insulin syringe graduation marks.

HealthRX prescribing clinicians default to the 5 mg/mL concentration for exactly this reason: every common dose from 1.0 mg to 2.5 mg falls on an exact 5-unit increment with no interpolation required.

Storage, Stability, and Beyond-Use Dating

Reconstituted PT-141 stored at 2 to 8°C with benzyl alcohol preservation retains greater than 95% purity for up to 28 to 30 days per USP 797 beyond-use date standards for compounded sterile preparations [3]. Exposure to temperatures above 25°C or to direct light accelerates peptide degradation. Do not freeze reconstituted peptide solutions. Freezing can cause benzyl alcohol to precipitate and can damage the peptide secondary structure.

Lyophilized (unreconstituted) vials remain stable at room temperature (below 25°C) for 12 to 24 months when stored away from moisture and light [5]. Once punctured, even an unreconstituted vial is considered open and should be used within the manufacturer's or pharmacy's stated beyond-use window.

A useful quality check: fresh reconstituted PT-141 at 5 mg/mL should appear water-clear. Any yellow tint, cloudiness, or visible particles suggests degradation or contamination and is grounds for discarding the vial.

Safety Considerations Specific to Reconstitution and Injection

Blood Pressure Monitoring

The RECONNECT Phase III program (N=1,267 across two trials) documented transient blood pressure increases in approximately 40% of bremelanotide users, with mean systolic increases of about 3 mmHg and diastolic increases of about 1.5 mmHg peaking at 4 hours post-dose [2]. The FDA prescribing information for Vyleesi states that bremelanotide is contraindicated in patients with uncontrolled hypertension or cardiovascular disease [1].

Patients self-administering compounded PT-141 should check blood pressure before the first dose and approximately 1 hour after. A baseline systolic above 150 mmHg warrants a clinician conversation before proceeding.

Nausea Management

Nausea is the most common adverse effect, reported in 40% of Phase III participants receiving 1.75 mg [2]. The FDA label recommends administering antiemetic prophylaxis if needed. Starting at a lower dose (1.0 mg) for the first one to two doses allows individual tolerability assessment before escalating to the standard 1.75 mg dose.

Injection Site Reactions

Localized hyperpigmentation at injection sites occurs in a minority of users, related to MC1R activation. This is a class effect of melanocortin peptides and does not indicate infection or allergic reaction [1]. Rotating sites reduces cumulative local exposure.

Sharps Disposal

All needles and syringes must be disposed of in an FDA-cleared sharps container. Never recap needles with two hands. Use the one-hand scoop technique if capping is necessary between draw and injection. Check your state's regulations for approved sharps disposal methods; most states permit FDA-cleared sharps containers for home disposal or have mail-back programs [4].

Common Reconstitution Errors and How to Avoid Them

| Error | Consequence | Prevention | |-------|-------------|------------| | Adding sterile water instead of BWFI | Vial must be discarded after single use | Read the label twice before drawing | | Injecting BWFI directly onto powder cake | Foaming, air bubbles, inaccurate draw | Aim stream at the glass wall | | Shaking instead of swirling | Peptide denaturation, visible aggregates | Gentle swirl only | | Using a 25 gauge or coarser injection needle | Increased pain, tissue trauma | Stock 27 to 29 gauge needles only | | Drawing at the wrong unit mark | Under- or over-dosing | Verify at eye level; meniscus bottom equals true volume | | Storing reconstituted vial in door of fridge | Temperature fluctuation degrades peptide | Store in the main body of the refrigerator | | Skipping site rotation | Lipohypertrophy, erratic absorption | Maintain a written rotation log |